China Fund News Taylor
Wang Sicong was banned from Weibo. The page shows that the user is currently banned for violating relevant laws and regulations.
About Wang Sicong being banned, some say it is a friend of Lianhua Qingwen Controversial remarks in the circle. The specifics are not yet known.
And a few days ago, Wang Sicong forwarded a video about Hua Qingwen on Weibo, with a text saying “the China Securities Regulatory Commission should strictly investigate Yiling Pharmaceutical.” About an hour later, Wang Sicong edited the Weibo again, deleting the words that the regulatory authorities should strictly investigate Yiling Pharmaceutical.
This video is from the media “bedtime news editor”, questioning “Lianhuaqing” “Ben is recommended by the World Health Organization” is a hype out of context, and it is said that a paper published in “Botanical Medicine” by Jia Zhenhua, the director of Hebei Yiling Hospital, is the corresponding author, concealing the relationship between the author and Yiling Pharmaceutical, and the objectivity is questionable . On the same day, Yiling Pharmaceutical’s stock price fell by the intraday limit.
In response to the remarks on the Internet, Yiling Pharmaceutical will soon A positive response said: “About the news on Weibo, please point out the specific questions and sources, and we will answer the specific content. From clinical trials, to specific experimental data, to being included in the new coronary pneumonia diagnosis and treatment plan, Including indications and instructions, we have complete evidence and report disclosure. You can’t ask questions at will because of the three words ‘Wang Sicong’. For some remarks on the Internet, just listen to it, investors please screen. “< /p>
On April 17, Dr. Lilac published the article “Don’t Eat Lianhua Qingwen to Prevent New Crown” , believes that from the three dimensions of official, clinical, and drug research and development, there is currently no effective evidence to support “Lianhua Qingwen can prevent new crowns.” It may have side effects if taken as a preventive medicine. “A drug that does not prevent the new crown is distributed in large quantities to healthy people who are not infected, and we don’t think that should be the case.”
Previous news shows that Yiling Pharmaceutical has donated 60 million yuan to Lianhua Qingwen to assist Shanghai epidemic prevention through the Lianhua respiratory health charity project of the Chinese Red Cross Foundation. control.
Affected by the news, Yiling Pharmaceutical has two consecutive trading days on the 15th and 18th. Limit down. On the 19th, Yiling Pharmaceutical Co., Ltd. oscillated and rebounded after the opening of the market, and closed slightly red. After-hours data showed that the four institutions sold a total of 305 million yuan today, and the Shenzhen Stock Connect sold 399 million yuan and bought 177 million yuan.
According to the company’s financial report, in the first three quarters of 2021, Yiling Pharmaceutical’s Lianhua Qingwen products achieved an operating income of 3.37 billion yuan, accounting for the company’s 41.6% of the total operating income. Since the beginning of this year, the stock price of Yiling Pharmaceutical has risen rapidly, with the highest cumulative increase of 112%, and the market value once reached 72 billion yuan, a record high.
According to public information, Yiling Pharmaceutical Lianhua Qingwen is the most frequently recommended patented Chinese patent medicine in the diagnosis and treatment plan of new coronary pneumonia. The fourth edition to the eighth edition all recommend taking the Chinese patent medicine Lianhua Qingwen for the prevention and treatment of patients with fatigue and fever during the medical observation period.
The company announced that in the “New Coronavirus” In the Diagnosis and Treatment Plan for Viral Pneumonia (Trial Version 9), in addition to continuing to list Lianhua Qingwen Capsules (granules) as the recommended drugs during the observation period of TCM treatment, it also lists them as mild and common during the clinical treatment period (confirmed cases). type recommended drug.
In response to the above disputes and doubts, on April 18, Yiling Pharmaceutical Co., Ltd. Respond.
What is the company’s response to the online questioning that Yiling Pharmaceutical released the information that “Lianhua Qingwen was recommended by the World Health Organization” to push up the stock price?
Yiling Pharmaceuticals: The company has never stated “WHO” recommendation on any occasion “Lianhua Qingwen”, not to mention that this information affects the stock price. The “World Health Organization Expert Evaluation Meeting on Chinese Medicine Treatment of New Coronary Pneumonia” recognizes the efficacy of traditional Chinese medicine including Lianhua Qingwen on new coronary pneumonia.
WHO The expert evaluation meeting for medical treatment of COVID-19 was held in the form of a video conference from February 28 to March 2. 21 international experts from 6 WHO regional offices focused on clinical practice, scientific research and evidence-based evaluation. A seminar was held to exchange and evaluate the reports shared by Chinese experts on the treatment of new coronary pneumonia with traditional Chinese medicine, and formed an expert evaluation meeting report.
Shared by Chinese experts In the relevant report on the treatment of new coronary pneumonia with traditional Chinese medicine, the report of “Prospective, Randomized, Controlled, Multi-Center Clinical Study of Traditional Chinese Medicine Lianhua Qingwen Capsules in the Treatment of Novel Coronavirus Pneumonia” published in “Phytomedicine” was cited. Related research results (page 8 of the report). The study was jointly participated by 23 designated hospitals for new coronary pneumonia across the country, and a total of 284 clinical cases were included. 4 capsules/time, 1 bag of granules, 3 times/day), the course of treatment is 14 days. The results of the study showed that the improvement rate of the main clinical symptoms (fever, fatigue, cough, etc.) of the Lianhua Qingwen treatment group was significantly higher than that of the control group, the duration of symptoms was significantly shortened, and the clinical cure rate was effectively improved.
the above Is the author of the paper Jia Zhenhua, president of Hebei Yiling Hospital, and there is an objectivity dispute for concealing the relationship with Yiling Pharmaceutical?
Yiling Pharmaceutical: There are 19 authors of the paper on the effect of Lianhua Qingwen in the treatment of new coronary pneumonia. The project is fully presided over by Academician Zhong Nanshan, and the clinical observation part is independently presided over by him. Professor Jia Zhenhua is listed as one of the authors for participating in the design of the project He did not participate in clinical observation and data processing. The publication of the paper has been explained to the publisher. The provision of some funds by Yiling Pharmaceuticals for this research and the research on drugs have been clarified by the editorial department of Phytomedicine and made publicly available for review, published in the 93rd issue of 2021.
connect Can Huaqingwen Capsules be used to prevent new crowns? Has the company ever released information about Lianhua Qingwen’s prevention of the new crown?
Yiling Pharmaceutical: “Efficacy and Safety Study of Lianhua Qingwen Capsules in the Prevention of Novel Coronavirus Pneumonia: A Prospective Open-Label Controlled Trial” A real-world research paper published in the international journal “Evidence-Based Complementary and Alternative” in November 2021 Medicine. The results of the study confirmed that the positive rate of nucleic acid detection in the Lianhua Qingwen intervention group was 0.27%, which was significantly lower than the positive rate of 1.14% in the control group (with statistical significance), and the preventive application of Lianhua Qingwen in the close contact group could reduce the positive infection rate of new coronary pneumonia by 76% , while the security is good.